Legal Opinion
G.D. Searle LLC v. Lupin Pharmaceuticals, Inc.
Court of Appeals for the Federal Circuit
Decided June 23, 2015No. 2014-1476PublishedCited by 5 opinions
1Opinion of the Court
BRYSON, Circuit Judge.
G.D. Searle LLC and Pfizer Asia Pacific Pte. Ltd. (collectively, “Pfizer”) appeal from a final judgment entered by the United States District Court for the Eastern District of Virginia. The court invalidated the relevant claims of Pfizer’s reissued U.S. Patent No. RE44,048 (“the RE '048 patent”) for obviousness-type double patenting. We affirm.
I
The doctrine of obviousness-type double patenting is intended to prevent the extension of the term of a patent by prohibiting the issuance of the claims of a second patent that are not patentably distinct from the claims of the…
2Cases cited7 opinions
- Amgen Inc. v. F. Hoffmann-La Roche Ltd.Court of Appeals for the Federal Circuit · 2009
- Pfizer, Inc. v. Teva Pharmaceuticals USA, Inc.Court of Appeals for the Federal Circuit · 2008
- Boehringer Ingelheim International GmbH v. Barr Laboratories, Inc.Court of Appeals for the Federal Circuit · 2010
- Eli Lilly and Co. v. Teva Parenteral Medicines, Inc.Court of Appeals for the Federal Circuit · 2012
- In Re Kozaburo Harita, Kukiyoshi Ajisawa, Kinji Iizuke, Yukihiko Kinoshita, Tetsuhide Kamijo, and Michihiro KobayashiCourt of Appeals for the Federal Circuit · 1988
2 more not listed; retrieve them via the Exa API.
3Cited by5 opinions
- Natural Alternatives Int'l, Inc. v. IancuCourt of Appeals for the Federal Circuit · 2018
- In Re: Janssen Biotech, Inc.Court of Appeals for the Federal Circuit · 2018
- ACADIA Pharmaceuticals Inc. v. Aurobindo Pharma LimitedDistrict Court, D. Delaware · 2023
- Janssen Biotech, Inc. v. Celltrion Healthcare Co.District Court, D. Massachusetts · 2016
- Janssen Biotech, Inc. v. Celltrion Healthcare Co.District Court, D. Massachusetts · 2016